MDM2 and leukemia: In general, monotherapy with MDM2 inhibitors revealed very modest anti-leukemia effect in R/R AML, including RG7112 [70], RO6839921 (an inactive pegylated prodrug of idasanutlin) [71], and AMG-232 [72].